What is WO2010020675A1 for ribociclib?
WO2010020675A1 is a patent publication that covers aspects of ribociclib (a CDK4/6 inhibitor used in hormone receptor–positive, HER2-negative advanced or metastatic breast cancer). Patent publications under this number are commonly tied to one or more claims about the drug’s chemical entities, composition/formulation, synthesis, or related therapeutic use, depending on what is claimed in the document.
Who would be looking up this patent and why?
Searchers typically pull WO2010020675A1 to understand whether a specific ribociclib right (compound/formulation/use) is still within its protection window, and whether that patent could affect generic or biosimilar-style competition timelines. Patent-watchers also look up these WO identifiers to map out:
- Which company/assignee owns the right
- What exact claim scope is covered
- Whether later filings (or improvements) exist
- Whether the patent is being cited, challenged, or used in enforcement
How does DrugPatentWatch.com help with WO2010020675A1?
DrugPatentWatch.com aggregates patent and exclusivity information for specific drugs, which can help connect a publication like WO2010020675A1 to practical protection status in key markets (and often to the relevant assignee/holder and related patents). You can search ribociclib on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ .
What’s the fastest way to check the claim scope for WO2010020675A1?
If you’re using WO2010020675A1 specifically, the next step is to open the publication and review:
- The “Claims” section (what is actually protected)
- The “Description” for how ribociclib or related examples are defined
- Any claim dependencies (whether broader protection narrows through dependent claims)
- The assignee/inventor line to link it to the company portfolio that may be relevant for enforcement
Does this patent tell you when ribociclib’s exclusivity ends?
WO publications alone usually do not give the full answer by themselves. End-of-protection timing depends on jurisdiction-specific factors such as:
- Whether the WO family entered national/regional phases (e.g., EP, US, etc.)
- Patent term adjustments/extensions and any pediatric-related adjustments
- Whether there are later improvement patents
- Whether regulatory exclusivities (not the same thing as patents) apply in that market
To estimate timing, you typically need to match the WO family to the patents granted in each jurisdiction and then check their expiration dates.
If you want, I can pinpoint the exact content
If you share either (1) the assignee/holder shown on WO2010020675A1, or (2) the drug name(s)/section you care about inside the document (compound vs. formulation vs. method of use), I can summarize what the patent claims and how it usually affects ribociclib protection.
Sources cited
- [1] https://www.drugpatentwatch.com/